Abrdn Life Sciences Investors (NYSE:HQL) Short Interest Down 10.8% in September

Abrdn Life Sciences Investors (NYSE:HQL) saw a large decrease in short interest during the month of September. As of September 15th, there was short interest totalling 154,100 shares, a decrease of 10.8% from the August 31st total of 172,800 shares. Based on an average daily volume of 95,000 shares, the days-to-cover ratio is currently 1.6 days.

Abrdn Life Sciences Investors Stock Down 0.3 %

NYSE:HQL opened at $14.95 on Friday. The firm’s fifty day moving average is $15.23 and its 200-day moving average is $14.25. Abrdn Life Sciences Investors has a 52 week low of $11.34 and a 52 week high of $15.90.

Abrdn Life Sciences Investors Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Stockholders of record on Friday, August 23rd will be paid a $0.49 dividend. This is a positive change from Abrdn Life Sciences Investors’s previous quarterly dividend of $0.48. This represents a $1.96 dividend on an annualized basis and a dividend yield of 13.11%. The ex-dividend date of this dividend is Friday, August 23rd.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Sanctuary Advisors LLC bought a new position in Abrdn Life Sciences Investors during the second quarter worth $154,000. Cetera Investment Advisers boosted its stake in Abrdn Life Sciences Investors by 6.9% during the second quarter. Cetera Investment Advisers now owns 156,384 shares of the company’s stock worth $2,216,000 after acquiring an additional 10,137 shares in the last quarter. Wedbush Securities Inc. boosted its stake in Abrdn Life Sciences Investors by 8.2% during the second quarter. Wedbush Securities Inc. now owns 16,673 shares of the company’s stock worth $236,000 after acquiring an additional 1,261 shares in the last quarter. Blue Bell Private Wealth Management LLC boosted its stake in Abrdn Life Sciences Investors by 97.6% during the second quarter. Blue Bell Private Wealth Management LLC now owns 62,244 shares of the company’s stock worth $882,000 after acquiring an additional 30,750 shares in the last quarter. Finally, Commonwealth Equity Services LLC boosted its stake in Abrdn Life Sciences Investors by 2.6% during the second quarter. Commonwealth Equity Services LLC now owns 33,788 shares of the company’s stock worth $479,000 after acquiring an additional 868 shares in the last quarter. 32.21% of the stock is owned by institutional investors.

Abrdn Life Sciences Investors Company Profile

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.